GERON CORP GERN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-6.02
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$83.5M | — | — | $225.9M |
| 2024 | — | -$174.6M | — | -$219.3M | $280.3M |
| 2023 | $237,000 | -$184.1M | — | -$168.6M | $247.9M |
| 2022 | $596,000 | -$141.9M | — | -$127.8M | $80.0M |
| 2021 | $1.4M | -$116.1M | — | -$95.8M | $126.4M |
| 2020 | $253,000 | -$75.6M | — | -$67.1M | $210.9M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Spiegel Robert J. | director | 2026-03-31 | Grant | 5,243 | $1.49 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -6.02 (distress)
- Working capital / assets 0.716
- Retained earnings / assets -3.253
- EBIT / assets -0.12
- Equity / liabilities 0.655
Source: SEC EDGAR filings · CIK 0000886744 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.